Associations between functional FCGR2A R131H and FCGR3A F158V polymorphisms and responsiveness to TNF blockers in spondyloarthropathy, psoriasis and Crohn's disease

A meta-analysis

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Aim: The aim of the current study was to investigate whether FCGR polymorphisms are associated with responsiveness to anti-TNF-α therapy in patients with spondyloarthropathy, psoriasis, and Crohn's disease. Materials & methods: We conducted a meta-analysis to evaluate the association between the functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to TNF blockers. Results: The meta-analysis indicated that responsiveness to TNF blockers was associated with the FCGR3A V allele (odds ratio: 3.308; 95% CI: 1.053-10.39; p = 0.040) and the FCGR2A RR + RH genotype (odds ratio: 3.904; p = 0.027) in patients with a follow-up time of ≥6 months. Conclusion: FCGR3A V and FCGR2A R allele carriers show better responsiveness to anti-TNF-α therapy in patients with follow-up times ≥6 months.

Original languageEnglish
Pages (from-to)1465-1477
Number of pages13
JournalPharmacogenomics
Volume17
Issue number13
DOIs
Publication statusPublished - 2016 Aug 1

Fingerprint

Spondylarthropathies
Psoriasis
Crohn Disease
Meta-Analysis
Alleles
Odds Ratio
Genotype
Therapeutics

Keywords

  • FCGR polymorphism
  • responsiveness
  • spondyloarthropathy
  • TNF blockers

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

@article{c47f6b8d07ce4d22a1c6a92ec623acc2,
title = "Associations between functional FCGR2A R131H and FCGR3A F158V polymorphisms and responsiveness to TNF blockers in spondyloarthropathy, psoriasis and Crohn's disease: A meta-analysis",
abstract = "Aim: The aim of the current study was to investigate whether FCGR polymorphisms are associated with responsiveness to anti-TNF-α therapy in patients with spondyloarthropathy, psoriasis, and Crohn's disease. Materials & methods: We conducted a meta-analysis to evaluate the association between the functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to TNF blockers. Results: The meta-analysis indicated that responsiveness to TNF blockers was associated with the FCGR3A V allele (odds ratio: 3.308; 95{\%} CI: 1.053-10.39; p = 0.040) and the FCGR2A RR + RH genotype (odds ratio: 3.904; p = 0.027) in patients with a follow-up time of ≥6 months. Conclusion: FCGR3A V and FCGR2A R allele carriers show better responsiveness to anti-TNF-α therapy in patients with follow-up times ≥6 months.",
keywords = "FCGR polymorphism, responsiveness, spondyloarthropathy, TNF blockers",
author = "Lee, {Young Ho} and Sungjae Choi and Ji, {Jong Dae} and Song, {Gwan Gyu}",
year = "2016",
month = "8",
day = "1",
doi = "10.2217/pgs.16.27",
language = "English",
volume = "17",
pages = "1465--1477",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "13",

}

TY - JOUR

T1 - Associations between functional FCGR2A R131H and FCGR3A F158V polymorphisms and responsiveness to TNF blockers in spondyloarthropathy, psoriasis and Crohn's disease

T2 - A meta-analysis

AU - Lee, Young Ho

AU - Choi, Sungjae

AU - Ji, Jong Dae

AU - Song, Gwan Gyu

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Aim: The aim of the current study was to investigate whether FCGR polymorphisms are associated with responsiveness to anti-TNF-α therapy in patients with spondyloarthropathy, psoriasis, and Crohn's disease. Materials & methods: We conducted a meta-analysis to evaluate the association between the functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to TNF blockers. Results: The meta-analysis indicated that responsiveness to TNF blockers was associated with the FCGR3A V allele (odds ratio: 3.308; 95% CI: 1.053-10.39; p = 0.040) and the FCGR2A RR + RH genotype (odds ratio: 3.904; p = 0.027) in patients with a follow-up time of ≥6 months. Conclusion: FCGR3A V and FCGR2A R allele carriers show better responsiveness to anti-TNF-α therapy in patients with follow-up times ≥6 months.

AB - Aim: The aim of the current study was to investigate whether FCGR polymorphisms are associated with responsiveness to anti-TNF-α therapy in patients with spondyloarthropathy, psoriasis, and Crohn's disease. Materials & methods: We conducted a meta-analysis to evaluate the association between the functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to TNF blockers. Results: The meta-analysis indicated that responsiveness to TNF blockers was associated with the FCGR3A V allele (odds ratio: 3.308; 95% CI: 1.053-10.39; p = 0.040) and the FCGR2A RR + RH genotype (odds ratio: 3.904; p = 0.027) in patients with a follow-up time of ≥6 months. Conclusion: FCGR3A V and FCGR2A R allele carriers show better responsiveness to anti-TNF-α therapy in patients with follow-up times ≥6 months.

KW - FCGR polymorphism

KW - responsiveness

KW - spondyloarthropathy

KW - TNF blockers

UR - http://www.scopus.com/inward/record.url?scp=84982091422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982091422&partnerID=8YFLogxK

U2 - 10.2217/pgs.16.27

DO - 10.2217/pgs.16.27

M3 - Review article

VL - 17

SP - 1465

EP - 1477

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 13

ER -